The Adjuvant Puzzle in Biliary Tract Cancer Surgery
A recent correspondence in The Lancet Gastroenterology & Hepatology critically examines the challenges of demonstrating efficacy for adjuvant therapies following surgical resection for biliary tract cancer. The discussion centers on a phase 2 trial of adjuvant camrelizumab and capecitabine for intrahepatic cholangiocarcinoma, highlighting the inherent difficulty in identifying a clear survival signal in the postoperative setting. This underscores a pivotal issue in surgical oncology: determining which patients benefit most from aggressive adjuvant regimens after complex hepatobiliary and pancreatic surgeries to improve long-term surgical outcomes and reduce postoperative recurrence.
Study Significance: For surgeons specializing in hepatobiliary and pancreatic procedures, this analysis reinforces the critical need for robust clinical trial design in the adjuvant space. It directly impacts perioperative care strategies and shared decision-making, emphasizing that postoperative therapy selection must be guided by high-quality evidence to avoid unnecessary treatment and its associated complications. This calls for a more nuanced approach to surgical oncology, where enhanced recovery protocols are integrated with data-driven adjuvant plans.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
